Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 2,437 Cr.
- Current Price ₹ 398
- High / Low ₹ 582 / 133
- Stock P/E
- Book Value ₹ 136
- Dividend Yield 0.00 %
- ROCE -4.68 %
- ROE -5.03 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.01 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.55% over past five years.
- Company has a low return on equity of -6.40% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | |
582 | 643 | 541 | 505 | 509 | 591 | 490 | 548 | 674 | 558 | 579 | 585 | |
Operating Profit | -72 | 44 | 112 | 39 | 84 | -134 | 54 | 77 | -13 | -98 | -20 | -26 |
OPM % | -14% | 6% | 17% | 7% | 14% | -29% | 10% | 12% | -2% | -21% | -4% | -5% |
183 | 28 | 70 | 62 | 8 | 338 | -14 | 9 | 1,687 | 154 | 62 | 57 | |
Interest | 150 | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 |
Depreciation | 71 | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 |
Profit before tax | -111 | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 |
Tax % | 2% | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% |
-113 | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | |
EPS in Rs | -18.29 | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -2% |
5 Years: | 1% |
3 Years: | -5% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | 12% |
3 Years: | 21% |
TTM: | -58% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 18% |
3 Years: | 47% |
1 Year: | 205% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -6% |
Last Year: | -5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 507 | 449 | 426 | 350 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 |
1,060 | 1,111 | 1,105 | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | 22 | |
371 | 364 | 317 | 440 | 349 | 379 | 449 | 587 | 848 | 407 | 378 | 433 | |
Total Liabilities | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
1,276 | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 601 | |
CWIP | 172 | 155 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 94 |
Investments | 16 | 15 | 9 | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 |
479 | 616 | 614 | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 517 | 592 | |
Total Assets | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
54 | 37 | 91 | 131 | 118 | 105 | -30 | 107 | -108 | -422 | -0 | -27 | |
-38 | -37 | 16 | -26 | 55 | -6 | -35 | -48 | 1,283 | 430 | 10 | 65 | |
-30 | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | -3 | -3 | |
Net Cash Flow | -14 | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | -10 | 7 | 35 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 68 | 52 | 79 | 95 | 84 | 71 | 46 | 49 | 45 | 48 | 37 | 47 |
Inventory Days | 375 | 404 | 516 | 770 | 651 | 173 | 344 | 311 | 296 | 292 | 282 | 391 |
Days Payable | 430 | 272 | 318 | 607 | 540 | 572 | 463 | 440 | 327 | 256 | 244 | 413 |
Cash Conversion Cycle | 13 | 184 | 278 | 259 | 195 | -328 | -73 | -80 | 14 | 83 | 76 | 25 |
Working Capital Days | -343 | -126 | 27 | -46 | -96 | -363 | 95 | -43 | -229 | -5 | -2 | 46 |
ROCE % | -8% | 0% | 4% | 2% | 3% | -16% | 4% | 5% | -6% | -10% | -4% | -5% |
Documents
Announcements
- Demat Status Report For The Month Of July 2025 7 Aug
-
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter Ended June 30, 2025
4 Aug - Board meeting on Aug 14 to approve Q1 2025 unaudited financial results; trading window closed till Aug 16.
-
Announcement under Regulation 30 (LODR)-Change in Management
31 Jul - VP Regulatory Affairs retires after 22 years, ceasing senior management role on July 31, 2025.
-
Intimation Under Regulation 30 And Regulation 31A(8) Of The Securities & Exchange Board Of India (LODR) Regulations, 2015 - Approval For Reclassification Of Mrs. Sunanda Jain, Mr. Sumit Jain And Ms. Radhika Jain From 'Promoters & Promoters' Group' Category To 'Public' Category Of Panacea Biotec Limited
29 Jul - Approval for reclassification of three promoters to public category; no change in promoter shareholding.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Jul - Newspaper copies regarding Notice intimating the shareholders about the opening of a Special Window for Re-lodgement of transfer requests of physical shares, in accordance with …
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix